Mona Mohammadhosseini

Mona Mohammadhosseini

Auto-generated profile, based on publicly available information

Mona Mohammadhosseini

Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MMMona Mohammadhosseini
Mona Mohammadhosseini
TETrevor Enright
Trevor Enright
ADAdam S DuVall
Adam S DuVall
ACAlex Chitsazan
Alex Chitsazan
HLHsin-Yun Lin
Hsin-Yun Lin
AAAnupriya Agarwal
Anupriya Agarwal
Familial platelet disorder (FPD) is associated with germline RUNX1 mutations, establishing a preleukemic state and increasing the risk of developing leukemia. Currently, there are no intervention strategies to prevent leukemia progression. Single-cell RNA sequencing ( n = 10) combined with functional analysis of samples from patients with RUNX1 -FPD ( n > 75) revealed that FPD hematopoietic stem and progenitor cells (HSPCs) displayed increased myeloid differentiation and suppressed megakaryopoiesis because of increased activation of prosurvival and inflammatory pathways. Bone marrow from patients with RUNX1 -FPD contained an elevated cytokine milieu, exerting chronic inflammatory stress on HSPCs. RUNX1 -FPD HSPCs were myeloid biased, had increased self-renewal, and were resistant to inflammation-mediated exhaustion. The bone marrow from patients with RUNX1 -FPD showed high transcript and protein expression of CD74 at the preleukemic stage compared with that of healthy controls, which remained high upon patient transformation into leukemia. Further, CD74-mediated signaling was exaggerated in RUNX1 -FPD HSPCs compared with healthy controls, leading to the activation of mTOR and JAK/STAT pathways with increased cytokine production. Genetic and pharmacological targeting of CD74 with ISO-1 and its downstream targets JAK1/2 and mTOR reversed RUNX1 -FPD differentiation defects in vitro and in vivo and reduced inflammation. Our results highlight that inflammation is an early event in RUNX1 -FPD pathogenesis, and CD74 signaling is one of the drivers of this inflammation. The repurposing of JAK1/2i (ruxolitinib) and mTORi (sirolimus) and promoting the advancement of CD74 inhibitors in clinical settings as an early intervention strategy would be beneficial to improve the phenotype of patients with RUNX1 -FPD and prevent myeloid progression.

7 March 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RMRucha V. Modak
Rucha V. Modak
KRKatia G. de Oliveira Rebola
Katia G. de Oliveira Rebola
JMJohn McClatchy
John McClatchy
MMMona Mohammadhosseini
Mona Mohammadhosseini
ADAlisa Damnernsawad
Alisa Damnernsawad
AAAnupriya Agarwal
Anupriya Agarwal
Purpose: Emerging evidence underscores the critical role of extrinsic factors within the microenvironment in protecting leukemia cells from therapeutic interventions, driving disease progression, and promoting drug resistance in acute myeloid leukemia (AML). This finding emphasizes the need for the identification of targeted therapies that inhibit intrinsic and extrinsic signaling to overcome drug resistance in AML. Experimental Design: We performed a comprehensive analysis utilizing a cohort of ∼300 AML patient samples. This analysis encompassed the evaluation of secreted cytokines/growth factors, gene expression, and ex vivo drug sensitivity to small molecules. Our investigation pinpointed a notable association between elevated levels of CCL2 and diminished sensitivity to the MEK inhibitors (MEKi). We validated this association through loss-of-function and pharmacologic inhibition studies. Further, we deployed global phosphoproteomics and CRISPR/Cas9 screening to identify the mechanism of CCR2-mediated MEKi resistance in AML. Results: Our multifaceted analysis unveiled that CCL2 activates multiple prosurvival pathways, including MAPK and cell-cycle regulation in MEKi-resistant cells. Employing combination strategies to simultaneously target these pathways heightened growth inhibition in AML cells. Both genetic and pharmacologic inhibition of CCR2 sensitized AML cells to trametinib, suppressing proliferation while enhancing apoptosis. These findings underscore a new role for CCL2 in MEKi resistance, offering combination therapies as an avenue to circumvent this resistance. Conclusions: Our study demonstrates a compelling rationale for translating CCL2/CCR2 axis inhibitors in combination with MEK pathway-targeting therapies, as a potent strategy for combating drug resistance in AML. This approach has the potential to enhance the efficacy of treatments to improve AML patient outcomes.

1 December 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
MAMohd Hafiz Ahmad
Mohd Hafiz Ahmad
MHMahesh Hegde
Mahesh Hegde
WWWaihay J. Wong
Waihay J. Wong
MMMona Mohammadhosseini
Mona Mohammadhosseini
LGLisa Garrett
Lisa Garrett
LCLucio H. Castilla
Lucio H. Castilla
Germ line mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). Patients with FPD frequently show clonal expansion of premalignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the premalignant bone marrow (BM) is not well-understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an FPD-associated mutation, Runx1R188Q. Immunophenotypic analysis showed an increase in the number of hematopoietic stem and progenitor cells (HSPCs) in the Runx1R188Q/+ mice. However, the comparison of Sca-1 and CD86 markers suggested that Sca-1 expression may result from systemic inflammation. Cytokine profiling confirmed the dysregulation of interferon-response cytokines in the BM. Furthermore, the expression of CD48, another inflammation-response protein, was also increased in Runx1R188Q/+ HSPCs. The DNA-damage response activity of Runx1R188Q/+ hematopoietic progenitor cells was defective in vitro, suggesting that Runx1R188Q may promote genomic instability. The differentiation of long-term repopulating HSCs was reduced in Runx1R188Q/+ recipient mice. Furthermore, we found that Runx1R188Q/+ HSPCs outcompete their wild-type counterparts in bidirectional repopulation assays, and that the genetic makeup of recipient mice did not significantly affect the clonal dynamics under this setting. Finally, we demonstrate that Runx1R188Q predisposes to HM in cooperation with somatic mutations found in FPDHM, using 3 mouse models. These studies establish a novel murine FPDHM model and demonstrate that germ line Runx1 mutations induce a premalignant phenotype marked by BM inflammation, selective expansion capacity, defective DNA-damage response, and predisposition to HM.

15 May 2024
Verified
Other
Open access
RMRucha V. Modak
Rucha V. Modak
KRKatia G. de Oliveira Rebola
Katia G. de Oliveira Rebola
JMJohn McClatchy
John McClatchy
MMMona Mohammadhosseini
Mona Mohammadhosseini
ADAlisa Damnernsawad
Alisa Damnernsawad
AAAnupriya Agarwal
Anupriya Agarwal
Cytokine levels in patient samples

15 May 2024
Verified
Other
Open access
RMRucha V. Modak
Rucha V. Modak
KRKatia G. de Oliveira Rebola
Katia G. de Oliveira Rebola
JMJohn McClatchy
John McClatchy
MMMona Mohammadhosseini
Mona Mohammadhosseini
ADAlisa Damnernsawad
Alisa Damnernsawad
AAAnupriya Agarwal
Anupriya Agarwal
Correlation and p values of cytokines and AUC for small molecules

15 May 2024
Verified
Other
Open access
RMRucha V. Modak
Rucha V. Modak
KRKatia G. de Oliveira Rebola
Katia G. de Oliveira Rebola
JMJohn McClatchy
John McClatchy
MMMona Mohammadhosseini
Mona Mohammadhosseini
ADAlisa Damnernsawad
Alisa Damnernsawad
AAAnupriya Agarwal
Anupriya Agarwal
GSEA analysis from trametinib-sensitive and resistant cells